The Value of Peripheral Blood Cell Ratios in Primary Membranous Nephropathy: A Single Center Retrospective Study
DOI: https://doi.org/10.2147/JIR.S404591
IF: 4.5
2023-03-10
Journal of Inflammation Research
Abstract:Ai-Hua Zhang, 1 Guang-Xia Dai, 2 Qi-Dong Zhang, 1 Hong-Dong Huang, 1 Wen-Hu Liu 1 1 Nephrology Department, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, People's Republic of China; 2 Endocrinology Department, Beijing Nanyuan Hospital, Beijing, People's Republic of China Correspondence: Hong-Dong Huang; Wen-Hu Liu, Nephrology Department, Capital Medical University Affiliated Beijing Friendship Hospital, No. 95 Yong An Road, Xi Cheng District, Beijing, 100050, People's Republic of China, Tel +86-10 63138579, Fax +86-10 63139144, Email ; Background: Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults. Forty percent of the patients continue to progress and eventually develop into chronic renal failure. Although phospholipase A2 receptor (PLA2R) is the major antigen of PMN, the clinical features do not often parallel with the antibody titers. Therefore, it is significant to find relative credible markers to predict the treatment response. Methods: One hundred and eighteen PMN patients were recruited. The response to treatment was defined as ALB≥ 30g/L at 6 months and complete remission (CR) or not at the end of the follow-up. Renal outcome endpoint was defined as 50% or more Cr increase at the end. Results: The patients with poor treatment effects had numerically higher platelet-lymphocytes ratio (PLR). For patients with CR or not, the difference was near to statistic significant ( P =0.095). When analyzing CR or not, the fitting of the binary logistic regression model including both PLA2R Ab titer and PLR (Hosmer–Lemeshow test: χ 2 =8.328, P = 0.402; OR (PLA2R Ab titer) = 1.002 (95% CI 1.000– 1.004, P = 0.042); OR (PLR) = 1.006 (95% CI 0.999– 1.013, P = 0.098)) was markedly better than that with only PLA2R Ab titer (Hosmer–Lemeshow test: χ 2 =13.885, P = 0.016). The patients with renal function deterioration showed significantly higher monocyte-lymphocyte ratio (MLR) (0.26 (0.22– 0.31) vs 0.18 (0.13– 0.22), P = 0.012). Conclusion: PMN patients with poor treatment response tended to have higher PLR at the time of renal biopsy, and a higher MLR was associated with poor renal outcomes. Our findings suggested that PLR and MLR might be used to predict treatment efficacy and prognosis for PMN patients, respectively. Keywords: membranous nephropathy, peripheral blood cell ratios, platelet-lymphocytes ratio, monocyte–lymphocyte ratio, treatment response, outcome Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults and can be primary or secondary. The antigenic target of antibodies in 70% of primary cases is phospholipase A2 receptor (PLA2R). 1 The specificity of PLA2R Ab for the lesion of MN nears 100%. 2 Yet, the correlation between antibody levels and clinical features in primary MN (PMN) is not intuitive, as changes in antibody levels tend to precede and predict clinical changes but with a significant lag time. 3 Early in the humoral immune response, low concentrations of autoantibody would engage podocyte antigen and rapidly be removed from the circulation, limiting detection by conventional clinical assays. The rapid elimination of low levels of PLA2R Ab from the circulation due to antigen binding has been termed the "sink hypothesis" and results from a very high affinity of PLA2R Ab for the N-terminal epitope in PLA2R. 3– 9 Therefore, it is significant to find relative credible markers to predict the response to treatment in patients with PMN. Accumulating data has begun to emerge that MN is associated with high inflammatory burden. 10,11 Recently, several studies have reported that some peripheral blood cell ratios, especially neutrophil–lymphocyte ratio (NLR), monocyte–lymphocyte ratio (MLR), platelet–lymphocyte ratio (PLR), and systemic immune-inflammation index (SII, calculated by platelet count × neutrophil count/lymphocyte count) serve as valuable biomarkers of inflammatory conditions and prognosis. For example, elevated NLR has been reported in inflammatory bowel disease, 12 diabetes mellitus, 13 gastrointestinal conditions, 14 thyroiditis, 15 and SARS CoV-2 infection. 16 In addition, thyroid conditions, 17 gastrointestinal diseases, 14 cancer, 18 diabetes mellitus, 19 irritable bowel disease, 20 and Covid-19 infection 21 are characterized with high PLR levels in blood. Finally, MLR is suggested as a disease marker in malignancy, 22 diabetic nephropathy, 23 functional bowel conditions,<sup -Abstract Truncated-
immunology